CVS Health — a massive enterprise that owns an insurer, a benefits management company, health clinics and retail pharmacies, among others — announced this month it is splitting off its pharmacy business into a completely separate company.
The reorganization follows years of criticism from officials in Louisiana and other states who complain that conglomerates like CVS wield too much power over the prescription drug market and are driving up costs.
But Louisiana leaders aren’t celebrating yet. They argue the fight to lower drug prices and force companies to reveal their murky business practices must continue.
“We’re not going to allow the future of healthcare in our community to be dictated by hidden profits and corporate consolidation,” said state Sen. Adam Bass, R-Bossier City, who this year played a lead role in passing tougher laws regulating the prescription drug market.
“We started this fight to change the system and, I mean as far as I’m concerned as well as my colleagues,” he said, “we intend to see it through.”
The federal government and states like Louisiana have kept up pressure on healthcare behemoths like CVS over their grip on the prescription drug market and the prices consumers pay for medications.
Regulators have argued the companies control too many parts of the prescription drug supply chain and accuse them of shrouding pricing practices in secrecy and raking in too much profit. There’s speculation that CVS’s restructuring is a response to that pressure.
CVS says the change is aimed at providing better, more affordable care to consumers.
“Our history is defined by proactively evolving to stay ahead of what’s next in healthcare, and in today’s environment, that means delivering more affordability, greater access, and a simpler experience,” David Joyner, chairman and CEO of CVS Health said in a statement.
The new business model is a planned and forward-thinking business move, the company says.
“Our decision is based on what is the best strategic long-term option for our businesses,” Amy Thibault, a CVS spokesperson, said in a statement. “The regulatory environment was only one of many factors in that review. We assessed many options and it was clear that by separating a strong, independent CVS Pharmacy we can create more value over the long-term for all stakeholders.”
What’s this all about?
Consumer spending on prescription drugs has increased significantly over the last few decades, as have concerns about the affordability of medications.
Six in 10 adults are worried about affording the cost of prescriptions, and four in 10 say they used cost-saving measures like skipping doses or not filling prescriptions, according to polling done in early 2026 by respected healthcare think tank KFF. About two-thirds of adults take at least one prescription drug, and six in 10 adults aged 65 and older report taking four or more medications, the poll shows.
Some officials have directed blame for the high prices at businesses known as pharmacy benefit managers, or PBMs.
PBMs act as middlemen in the complex prescription drug supply chain. Employers and insurers hire PBMs to administer prescription drug benefits. PBMs help determine which drugs are covered by an insurance plan, negotiate prices and discounts with drug manufacturers on behalf of the plan, contract with pharmacies that dispense drugs to patients and reimburse pharmacies for dispensing those drugs.
Three PBMs manage roughly 80% of prescription drug claims for approximately 270 million people, according to a 2024 Federal Trade Commission report. They are Caremark, owned by CVS; Express Scripts, owned by Cigna; and OptumRx, owned by UnitedHealth.
The six largest PBMs manage 94% of prescription drug claims in the U.S., the FTC report says.
“The Big 6 PBMs have become vertically integrated within massive conglomerates that provide a broad range of services across the pharmaceutical supply chain and other segments of the healthcare sector,” the report says. “Amidst increasing vertical integration and concentration, these powerful middlemen may be profiting by inflating drug costs and squeezing Main Street pharmacies.”
PBMs argue pharmaceutical companies set prices for the drugs they manufacture, and it’s the job of PBMs to negotiate lower costs for health insurance plans and patients.
“PBMs work on behalf of employers and unions to lower the cost of the pharmacy benefit they provide their employees and members,” Thibault, the CVS spokesperson, said. “The criticism the PBM industry has received rarely comes from the employers and unions who hire us to make their prescription benefit more affordable and safer for members.”
CVS Health is a massive company. In 2025, it brought in $402 billion in revenue, according to its financial reporting.
The company’s reorganization is slated to roll out in the first half of 2028.
Under that plan, CVS Health, an independent publicly traded company, will include Aetna, a health insurer; CVS Caremark, a pharmacy benefit manager; and CVS Specialty, a specialty pharmacy for rare or complex conditions. It will also include Oak Street Health, primary care for older adults, and Signify Health, an in-home health screening business.
A new, publicly traded company called CVS Pharmacy will include about 9,000 CVS retail pharmacies, its mail-order pharmacy and its walk-in MinuteClinics.
Louisiana officials weigh in
Louisiana lawmakers, as well as officials like Gov. Jeff Landry and Attorney General Liz Murrill, have spent the last few years bashing CVS and other healthcare conglomerates, accusing them of using their outsized influence to squash competition and jack up drug prices.
“The same corporate family can still influence which drugs your plan covers, where you fill them and what your pharmacist gets paid,” state Rep. Michael Echols, R-Monroe, a staunch critic of major PBMs and ally to Louisiana’s independent pharmacists, said of the CVS spin off. “That leaves patients holding the bag while big insurance and its pharmacy middlemen can still make money at multiple points on the same prescription.”
He added: “CVS can spin off 9,000 drugstores, but if Aetna, Caremark and CVS Specialty stay under one roof, it’s little more than rearranging deck chairs on a sinking ship.”
Lawmakers in 2025 threatened to ban companies from vertically integrating retail pharmacies and PBMs, which was fiercely opposed by CVS. This year, they elected to pause those efforts and instead pursue other measures.
PBMs in Louisiana now have to reimburse local, nonchain pharmacies at higher rates for the drugs they dispense. There are also new limits on how PBMs can charge for their services; they’re no longer allowed to tie their fees to the cost of a drug and instead must charge a flat fee.
Landry and Murrill have also used their positions in government to exert pressure on the companies.
Murrill sued CVS over alleged unfair trade practices last year; Louisiana and CVS settled the litigation in February. She also filed an antitrust lawsuit against Express Scripts this year.
Murrill has also continued to push forward a lawsuit initiated by Landry when he was attorney general against OptumRx, accusing the company of inflating the cost of drugs charged to the Louisiana’s Medicaid program.
Murrill declined to comment for this story.
In a separate 2023 lawsuit, Landry sued CVS Caremark, Express Scripts and OptumRx, saying the PBMs artificially raised the price of insulin and other diabetes medications.
Since then, as governor, Landry has often been fiercely critical of major PBMs, bemoaning their “shady pricing schemes” and saying in jest that the acronym stands for “profiteering big money.”
In 2025, Landry threatened to call legislators into a special session to pass laws prohibiting PBMs from owning retail pharmacies.
“My priority remains the same: lower prescription costs and make sure Louisianians can get their medicine at the pharmacy they trust,” Landry said in a statement.
Nationwide scrutiny
Louisiana is just one of a slew of players who are putting pressure on PBMs. The FTC sued the three largest PBMs last year, and this year Congress passed laws requiring more transparent business practices.
Many states are also calling for stronger PBM regulation.
Arkansas and Tennessee recently banned vertical integration of PBMs and pharmacies, passing state laws that prohibit PBMs that manage prescription drug benefits from owning pharmacies that dispense medications. PBMs are suing to block those laws.
Louisiana legislators have said they are waiting to see what happens with the litigation in other states before moving forward with a vertical integration ban here.